EXHIBIT 99.1
FOR IMMEDIATE RELEASE
CONTACTS:
Donald C. Weinberger
Donald W. Fallon, CFO Andria Pilo-Arena (Media)
CEPTOR CORPORATION, INC. WOLFE AXELROD WEINBERGER ASSOC. LLC
(410) 527-9998 Fax (410) 527-9867 (212) 370-4500 Fax (212) 370-4505
dfallon@ceptorcorp.com don@wolfeaxelrod.com;
- ---------------------- --------------------
andria@wolfeaxelrod.com
CEPTOR AND XMARK ANNOUNCE END TO LAW SUIT
HUNT VALLEY, MD - SEPTEMBER 21, 2005 -- CEPTOR CORPORATION, INC. (OTC BB: CEPO),
a development-stage biopharmaceutical company focusing on cell targeted
therapeutic products for neuromuscular and neurodegenerative diseases, and the
Xmark Opportunity Funds announced that Xmark has dropped the pending lawsuit
brought by it against CepTor Corporation and its Chairman, William Pursley, and
that Xmark has agreed to dismiss, with prejudice, all of Xmark's pending claims.
Both sides have provided the other with releases from any further actions.
Mr. Pursley stated, "We are happy to have resolved this matter amicably with
Xmark without the need for further wasteful litigation permitting us to focus
our attentions where they belong, on getting an IND filed for Myodur in Duchenne
muscular dystrophy."
-----------------------------------
About CepTor
CEPTOR CORPORATION is a development-stage biopharmaceutical company engaged in
the discovery, development, and commercialization of proprietary, cell-targeted
therapeutic products for the treatment of neuromuscular and neurodegenerative
diseases with a focus on orphan diseases. The Company's mission is to increase
the quality and quantity of life of people suffering with these diseases. An
orphan disease is defined in the United States as a serious or life-threatening
disease that affects less than 200,000 people and for which no definitive
therapy currently exists. CepTor Corporation seeks to create an efficient orphan
drug platform by taking advantage of the legislative, regulatory and commercial
opportunities common to these rare diseases. CepTor's primary efforts are
currently being focused on moving its lead product, MYODUR, into phase I/II
clinical trials for Duchenne muscular dystrophy. The Company's broad platform
technology also includes the development of products for multiple sclerosis,
retinal degeneration and epilepsy.
THIS NEWS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS. SUCH STATEMENTS ARE VALID
ONLY AS OF TODAY, AND WE DISCLAIM ANY OBLIGATION TO UPDATE THIS INFORMATION.
THESE STATEMENTS ARE SUBJECT TO KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES THAT
MAY CAUSE ACTUAL FUTURE EXPERIENCE AND RESULTS TO DIFFER MATERIALLY FROM THE
STATEMENTS MADE. THESE STATEMENTS ARE BASED ON OUR CURRENT BELIEFS AND
EXPECTATIONS AS TO SUCH FUTURE OUTCOMES. DRUG DISCOVERY AND DEVELOPMENT INVOLVE
A HIGH DEGREE OF RISK. FACTORS THAT MIGHT CAUSE SUCH A MATERIAL DIFFERENCE
INCLUDE, AMONG OTHERS, UNCERTAINTIES RELATED TO THE ABILITY TO ATTRACT AND
RETAIN PARTNERS FOR OUR TECHNOLOGIES, THE IDENTIFICATION OF LEAD COMPOUNDS, THE
SUCCESSFUL PRECLINICAL DEVELOPMENT THEREOF, THE COMPLETION OF CLINICAL TRIALS,
THE FDA REVIEW PROCESS AND OTHER GOVERNMENT REGULATION, OUR PHARMACEUTICAL
COLLABORATOR'S ABILITY TO SUCCESSFULLY DEVELOP AND COMMERCIALIZE DRUG
CANDIDATES, COMPETITION FROM OTHER PHARMACEUTICAL COMPANIES, PRODUCT PRICING AND
THIRD PARTY REIMBURSEMENT.
###
